Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 5 | 2007 | 48 | 0.770 |
Why?
|
| Breast Neoplasms | 12 | 2016 | 754 | 0.610 |
Why?
|
| Loss of Heterozygosity | 4 | 2004 | 20 | 0.500 |
Why?
|
| Endometrium | 7 | 2009 | 42 | 0.420 |
Why?
|
| Carcinoma in Situ | 5 | 1999 | 15 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 1999 | 16 | 0.300 |
Why?
|
| Endometrial Hyperplasia | 2 | 2007 | 11 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2003 | 158 | 0.280 |
Why?
|
| Carcinosarcoma | 2 | 2005 | 8 | 0.270 |
Why?
|
| Carcinoma, Ductal, Breast | 5 | 1999 | 30 | 0.260 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 1998 | 70 | 0.260 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2004 | 38 | 0.260 |
Why?
|
| Estrogen Receptor alpha | 1 | 2006 | 48 | 0.240 |
Why?
|
| Endometriosis | 1 | 2006 | 25 | 0.230 |
Why?
|
| Uterus | 1 | 2006 | 79 | 0.230 |
Why?
|
| Receptor, erbB-2 | 1 | 2005 | 65 | 0.230 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2004 | 5 | 0.220 |
Why?
|
| Apocrine Glands | 2 | 2002 | 2 | 0.200 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2002 | 7 | 0.200 |
Why?
|
| Female | 27 | 2016 | 20375 | 0.200 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1999 | 34 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2003 | 42 | 0.190 |
Why?
|
| Ovarian Neoplasms | 2 | 2000 | 103 | 0.170 |
Why?
|
| Papillomaviridae | 2 | 1998 | 22 | 0.170 |
Why?
|
| CA-125 Antigen | 1 | 2000 | 6 | 0.160 |
Why?
|
| Polycystic Ovary Syndrome | 3 | 2007 | 13 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1999 | 13 | 0.160 |
Why?
|
| Adnexal Diseases | 1 | 2000 | 6 | 0.160 |
Why?
|
| Humans | 29 | 2016 | 32967 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1999 | 28 | 0.160 |
Why?
|
| Hemangioma | 1 | 2000 | 22 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1999 | 40 | 0.160 |
Why?
|
| Carcinoma, Papillary | 2 | 1998 | 14 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 5 | 1999 | 199 | 0.150 |
Why?
|
| Leuprolide | 2 | 2009 | 5 | 0.150 |
Why?
|
| Luteal Phase | 2 | 2009 | 12 | 0.150 |
Why?
|
| Papilloma, Intraductal | 1 | 1998 | 1 | 0.150 |
Why?
|
| Estradiol | 3 | 2009 | 121 | 0.150 |
Why?
|
| Vulvar Neoplasms | 2 | 2002 | 8 | 0.130 |
Why?
|
| Progesterone | 2 | 2008 | 69 | 0.120 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2016 | 3 | 0.120 |
Why?
|
| DNA, Neoplasm | 4 | 2004 | 54 | 0.120 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 21 | 0.120 |
Why?
|
| Estrogens | 2 | 2007 | 169 | 0.110 |
Why?
|
| Adult | 14 | 2013 | 9586 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 1996 | 68 | 0.110 |
Why?
|
| Breast Neoplasms, Male | 2 | 2006 | 11 | 0.100 |
Why?
|
| Fallopian Tube Diseases | 1 | 2013 | 4 | 0.100 |
Why?
|
| Choristoma | 1 | 2013 | 14 | 0.100 |
Why?
|
| Granulosa Cells | 1 | 2013 | 11 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 43 | 0.090 |
Why?
|
| Fertility Agents, Female | 2 | 2009 | 5 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 2007 | 300 | 0.090 |
Why?
|
| Microsatellite Repeats | 2 | 2004 | 22 | 0.090 |
Why?
|
| RNA, Messenger | 5 | 2008 | 500 | 0.090 |
Why?
|
| Receptors, Androgen | 2 | 2002 | 43 | 0.090 |
Why?
|
| Diagnosis, Differential | 4 | 2003 | 527 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 4 | 2016 | 193 | 0.080 |
Why?
|
| Middle Aged | 9 | 2007 | 12203 | 0.080 |
Why?
|
| Integrin beta3 | 2 | 2009 | 3 | 0.080 |
Why?
|
| Menstrual Cycle | 2 | 2008 | 27 | 0.080 |
Why?
|
| Aged | 8 | 2007 | 10637 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2006 | 4065 | 0.070 |
Why?
|
| Uterine Diseases | 1 | 2008 | 9 | 0.070 |
Why?
|
| Keratins | 2 | 1999 | 37 | 0.070 |
Why?
|
| GATA3 Transcription Factor | 1 | 2008 | 2 | 0.070 |
Why?
|
| T-Box Domain Proteins | 1 | 2008 | 14 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2007 | 8 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2004 | 191 | 0.060 |
Why?
|
| Breast | 2 | 2004 | 64 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 98 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2006 | 821 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2006 | 35 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2005 | 10 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 42 | 0.060 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2004 | 3 | 0.060 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2004 | 3 | 0.060 |
Why?
|
| Hysterectomy | 2 | 2013 | 49 | 0.060 |
Why?
|
| Tissue Array Analysis | 1 | 2004 | 36 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 78 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 471 | 0.050 |
Why?
|
| Immunohistochemistry | 5 | 2007 | 497 | 0.050 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 220 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 92 | 0.050 |
Why?
|
| Nitroimidazoles | 1 | 2003 | 4 | 0.050 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2003 | 15 | 0.050 |
Why?
|
| Protein Precursors | 1 | 2003 | 19 | 0.050 |
Why?
|
| Histiocytosis, Sinus | 1 | 2003 | 3 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 475 | 0.050 |
Why?
|
| Hemangiosarcoma | 1 | 2003 | 9 | 0.050 |
Why?
|
| Hemangioendothelioma | 1 | 2003 | 11 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2003 | 469 | 0.050 |
Why?
|
| Pregnancy | 1 | 2006 | 981 | 0.050 |
Why?
|
| Ovulation Induction | 1 | 2002 | 3 | 0.050 |
Why?
|
| Anovulation | 1 | 2002 | 4 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 106 | 0.050 |
Why?
|
| Adolescent | 5 | 2009 | 3643 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2002 | 178 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2001 | 64 | 0.040 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2000 | 15 | 0.040 |
Why?
|
| Myocardium | 1 | 2001 | 192 | 0.040 |
Why?
|
| Ascites | 1 | 2000 | 15 | 0.040 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1999 | 19 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2008 | 255 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2001 | 212 | 0.040 |
Why?
|
| Alleles | 1 | 1999 | 253 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2000 | 265 | 0.040 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 1998 | 1 | 0.040 |
Why?
|
| Genes, p53 | 1 | 1998 | 23 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 1998 | 50 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 1998 | 35 | 0.040 |
Why?
|
| Liver | 1 | 2001 | 492 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1998 | 70 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1998 | 88 | 0.030 |
Why?
|
| Myometrium | 1 | 1997 | 9 | 0.030 |
Why?
|
| Uterine Hemorrhage | 1 | 1997 | 9 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 1997 | 23 | 0.030 |
Why?
|
| Risk Factors | 2 | 1996 | 4001 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1997 | 80 | 0.030 |
Why?
|
| Blood Vessels | 1 | 1997 | 51 | 0.030 |
Why?
|
| Prognosis | 2 | 2003 | 1547 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1997 | 162 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2003 | 2287 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 780 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1997 | 205 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 45 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1998 | 384 | 0.030 |
Why?
|
| Survival Rate | 1 | 1997 | 895 | 0.030 |
Why?
|
| Mice | 2 | 2016 | 2529 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1994 | 69 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1994 | 195 | 0.020 |
Why?
|
| Granulosa Cell Tumor | 1 | 2013 | 1 | 0.020 |
Why?
|
| Stromal Cells | 2 | 2004 | 67 | 0.020 |
Why?
|
| Leiomyoma | 1 | 2013 | 15 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 2013 | 29 | 0.020 |
Why?
|
| Epithelial Cells | 2 | 2004 | 129 | 0.020 |
Why?
|
| Incidence | 1 | 1996 | 1246 | 0.020 |
Why?
|
| Male | 6 | 2008 | 19754 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2003 | 134 | 0.020 |
Why?
|
| Genetic Markers | 2 | 2004 | 126 | 0.020 |
Why?
|
| Osteopontin | 1 | 2009 | 4 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 7599 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2008 | 15 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2008 | 115 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 51 | 0.020 |
Why?
|
| Organ Size | 1 | 2008 | 220 | 0.020 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Phenotype | 2 | 2000 | 644 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 622 | 0.020 |
Why?
|
| Gene Expression | 1 | 2008 | 336 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2007 | 3708 | 0.010 |
Why?
|
| Genomic Instability | 1 | 2004 | 6 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 19 | 0.010 |
Why?
|
| Cell Communication | 1 | 2004 | 29 | 0.010 |
Why?
|
| Metallothionein | 1 | 2003 | 3 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 38 | 0.010 |
Why?
|
| Hemangioma, Cavernous | 1 | 2003 | 3 | 0.010 |
Why?
|
| Mammography | 1 | 2003 | 40 | 0.010 |
Why?
|
| Oxygen | 1 | 2003 | 144 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 245 | 0.010 |
Why?
|
| Clomiphene | 1 | 2002 | 1 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2002 | 2 | 0.010 |
Why?
|
| Micromanipulation | 1 | 2002 | 2 | 0.010 |
Why?
|
| RNA Probes | 1 | 2002 | 4 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2002 | 6 | 0.010 |
Why?
|
| Thrombosis | 1 | 2003 | 81 | 0.010 |
Why?
|
| Dissection | 1 | 2002 | 17 | 0.010 |
Why?
|
| Axilla | 1 | 2002 | 17 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 43 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 20 | 0.010 |
Why?
|
| Infertility | 1 | 2002 | 15 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 2738 | 0.010 |
Why?
|
| Receptors, Vitronectin | 1 | 2002 | 1 | 0.010 |
Why?
|
| Calcinosis | 1 | 2003 | 146 | 0.010 |
Why?
|
| Androgens | 1 | 2002 | 28 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 238 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2001 | 20 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 727 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2001 | 71 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 290 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2001 | 134 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2001 | 290 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2000 | 26 | 0.010 |
Why?
|
| Lactation | 1 | 2000 | 16 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2000 | 72 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 436 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 160 | 0.010 |
Why?
|
| Child | 1 | 2006 | 2478 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 106 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 185 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2000 | 107 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 95 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1998 | 169 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 950 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 1610 | 0.010 |
Why?
|
| X Chromosome | 1 | 1997 | 27 | 0.010 |
Why?
|
| Metaplasia | 1 | 1997 | 19 | 0.010 |
Why?
|
| Heterozygote | 1 | 1997 | 61 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 2338 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 3460 | 0.010 |
Why?
|
| Mutation | 1 | 1997 | 499 | 0.010 |
Why?
|